The company's principal activities are the research, development and commercialization of therapeutics and technologies for the treatment of cancer. The company is a development stage biopharmaceutical company. The product portfolio consists of one drug delivery platform and two distinct small molecule anticancer agents. The company has acquired rights to certain oncology and antiviral related patents and technology. The company has developed small molecular weight, pharmaceutical agents with known mechanisms of activity.
